IQVIA Holdings Inc. $IQV Shares Sold by Gilliland Jeter Wealth Management LLC

Key Points

• Gilliland Jeter Wealth Management LLC significantly reduced its position in IQVIA Holdings by 65.7%, selling 2,541 shares and now holding 1,324 shares valued at approximately $209,000.
• IQVIA reported a strong quarterly earnings of $2.81 per share, exceeding analyst estimates and posting a 5.3% increase in revenue year-over-year, totaling $4.02 billion.
• The stock is currently rated as a "Moderate Buy" by analysts, with an average target price of $236.45 and 19 analysts recommending a buy versus 6 hold ratings.

Gilliland Jeter Wealth Management LLC reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 65.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,324 shares of the medical research company's stock after selling 2,541 shares during the period. Gilliland Jeter Wealth Management LLC's holdings in IQVIA were worth $209,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in IQV. Pacer Advisors Inc. increased its position in shares of IQVIA by 5,036.1% during the first quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after acquiring an additional 854,732 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after purchasing an additional 798,534 shares during the period. Hawk Ridge Capital Management LP purchased a new position in shares of IQVIA in the first quarter valued at approximately $77,096,000. Nuveen LLC purchased a new position in shares of IQVIA in the first quarter valued at approximately $76,328,000. Finally, Platinum Investment Management Ltd. purchased a new position in shares of IQVIA in the second quarter valued at approximately $61,585,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 1.3%

NYSE IQV opened at $203.16 on Friday. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $237.34. The company has a 50-day moving average of $188.70 and a 200-day moving average of $168.15. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $34.54 billion, a P/E ratio of 29.40, a P/E/G ratio of 2.20 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter in the prior year, the company posted $2.64 EPS. The company's quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on IQV shares. Robert W. Baird lifted their price target on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Cowen restated a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Evercore ISI boosted their price objective on shares of IQVIA from $220.00 to $240.00 and gave the stock an "outperform" rating in a research report on Wednesday. Redburn Partners set a $214.00 price objective on shares of IQVIA in a research report on Wednesday, September 3rd. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of IQVIA in a report on Wednesday. Nineteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $236.45.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.